2 weeks Ago By ABMN Staff
Renaissance Technologies LLC lessened its holdings in AstraZeneca PLC ( NASDAQ:AZN – Free Report ) by 91.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 57,500 shares of the company’s stock after selling 632,444 shares during the period.
Renaissance Technologies LLC’s holdings in AstraZeneca were worth $4,484,000 as of its most recent filing with the Securities and Exchange Commission. Several other hedge funds have also added to or reduced their stakes in AZN. Charles Schwab Investment Management Inc.
lifted its holdings in AstraZeneca by 19.7% during the 4th quarter. Charles Schwab Investment Management Inc.
now owns 147,251 shares of the company’s stock worth $9,917,000 after purchasing an additional 24,233 shares during the last quarter. Advisory Services Network LLC boosted its position in shares of AstraZeneca by 47.7% in the fourth quarter.
Advisory Services Network LLC now owns 13,813 shares of the company’s stock valued at $930,000 after acquiring an additional 4,459 shares during the period. Nomura Asset Management Co. Ltd.
grew its stake in shares of AstraZeneca by 3.1% in the fourth quarter. Nomura Asset Management Co.
Ltd. now owns 61,530 shares of the company’s stock valued at $4,144,000 after acquiring an additional 1,876 shares in the last quarter. Fiduciary Trust Co increased its position in AstraZeneca by 7.
2% during the fourth quarter. Fiduciary Trust Co now owns 6,712 shares of the company’s stock worth $452,000 after acquiring an additional 448 shares during the period. Finally, Dorsey & Whitney Trust CO LLC raised its stake in AstraZeneca by 1.
2% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 20,097 shares of the company’s stock worth $1,354,000 after purchasing an additional 242 shares in the last quarter. Institutional investors and hedge funds own 20.
35% of the company’s stock. AstraZeneca Trading Down 0.7 % Shares of AstraZeneca stock opened at $77.
62 on Friday. The stock has a market capitalization of $240.66 billion, a P/E ratio of 38.
05, a P/E/G ratio of 1.45 and a beta of 0.47.
The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.
89. The stock’s 50-day simple moving average is $81.68 and its 200 day simple moving average is $76.
97. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.
68. AstraZeneca Cuts Dividend The business also recently announced a Semi-Annual dividend, which was paid on Monday, September 9th. Investors of record on Friday, August 9th were issued a dividend of $0.
49 per share. This represents a yield of 1.8%.
The ex-dividend date of this dividend was Friday, August 9th. AstraZeneca’s dividend payout ratio is presently 48.04%.
Analyst Upgrades and Downgrades AZN has been the topic of several recent research reports. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th.
TD Cowen increased their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th.
Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Barclays upgraded shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company’s stock.
Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $89.75. View Our Latest Research Report on AstraZeneca AstraZeneca Company Profile ( Free Report ) AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Further Reading Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter .
.
